Free tool
FAERS Monitor: Oxervate
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming BLA 761094 or its brand name (Oxervate, Cenegermin-Bkbj). Reports on generic versions are filed under their own applications.
Reports
13,495
Serious
1,498
11% of reports
Hospitalization
799
Death reported
220
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- eye pain6,508
- eye irritation2,111
- product dose omission issue1,456
- ocular hyperaemia1,360
- photophobia1,209
- vision blurred1,053
- eye swelling959
- wrong technique in product usage process949
- ocular discomfort908
- lacrimation increased822
- eyelid pain797
- headache773
- off label use773
- product administration error660
- therapy interrupted609
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2017 | 1 |
| 2019 | 488 |
| 2020 | 661 |
| 2021 | 1,094 |
| 2022 | 1,926 |
| 2023 | 2,337 |
| 2024 | 2,274 |
| 2025 | 3,179 |
| 2026 | 1,535 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,040,664 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| eyelid painSignal | 797 | 1004.6 | 920.5 | 485,381 |
| eye painSignal | 6,508 | 203.1 | 199.1 | 1,160,704 |
| ocular discomfortSignal | 908 | 137.0 | 128.3 | 112,647 |
| photophobiaSignal | 1,209 | 107.0 | 101.2 | 118,777 |
| eye irritationSignal | 2,111 | 59.3 | 57.0 | 116,823 |
| product administration errorSignal | 660 | 52.6 | 48.7 | 32,287 |
| ocular hyperaemiaSignal | 1,360 | 46.0 | 43.7 | 58,178 |
| lacrimation increasedSignal | 822 | 43.6 | 40.7 | 33,255 |
| eye swellingSignal | 959 | 41.2 | 38.7 | 36,682 |
| therapy interruptedSignal | 609 | 13.4 | 12.4 | 6,932 |
| vision blurredSignal | 1,053 | 12.0 | 11.4 | 10,633 |
| product dose omission issueSignal | 1,456 | 7.8 | 7.4 | 8,632 |
| wrong technique in product usage processSignal | 949 | 7.3 | 6.9 | 5,206 |
| headache | 773 | 1.9 | 1.8 | 351 |
| off label use | 773 | 1.4 | 1.3 | 82 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.